Strides Pharma Science’s step?down wholly?owned subsidiary -- Strides Pharma Global has received approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.
The US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately $15 million. The product will be manufactured at the company’s flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market. The company has 124 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 38 are pending approval.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.